(Q38254893)

1 September 2017

1 reference

title

Quality of life in MPN comes of age as a therapeutic target (English)

1 reference

1 September 2017

Robyn M Scherber

1

1 reference

1 September 2017

Holly L Geyer

series ordinal

2

1 reference

1 September 2017

Ruben A Mesa

series ordinal

3

1 reference

1 September 2017

1 December 2014

1 reference

Current hematologic malignancy reports

1 September 2017

1 reference

1 September 2017

9

1 reference

1 September 2017

4

1 reference

1 September 2017

324-330

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-014-0239-9

1 September 2017

0 references

cites work

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

Skin mast cells in polycythaemia vera: relationship to the pathogenesis and treatment of pruritus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-014-0239-9

Nonhepatosplenic Extramedullary Hematopoiesis: Associated Diseases, Pathology, Clinical Course, and Treatment

21 January 2018

1 reference

12 December 2020

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

12 December 2020

Some speculations on the myeloproliferative syndromes.

1 reference

12 December 2020

The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory

1 reference

12 December 2020

The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue

1 reference

12 December 2020

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

1 reference

12 December 2020

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis

1 reference

12 December 2020

Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups

1 reference

12 December 2020

10.1007/S11899-014-0239-9

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

0 references

1 reference